<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912258</url>
  </required_header>
  <id_info>
    <org_study_id>PIDUC</org_study_id>
    <nct_id>NCT04912258</nct_id>
  </id_info>
  <brief_title>Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis</brief_title>
  <official_title>Trans-arterial Chemoembolization With Irinotecan Drug-eluting Beads Before Liver Surgery for Patients With Primary Unresectable Colorectal Liver Metastasis: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for&#xD;
      patients with primarily unresectable colorectal liver metastasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver relapse-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>from liver surgery to liver relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DEB-TACE before liver surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>direct liver surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans arterial chemoembolization with Irinotecan Drug-eluting Beads</intervention_name>
    <description>preoperative chemoembolization with Irinotecan Drug-eluting Beads</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Irinotecan Drug-eluting Beads</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Histologically proven colorectal liver metastasis；&#xD;
&#xD;
          -  With liver-dominant disease；&#xD;
&#xD;
          -  Primarily evaluated as potentially resectable and conversed successfully&#xD;
&#xD;
          -  Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l,&#xD;
             platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 (within 1 week prior&#xD;
             to randomization)&#xD;
&#xD;
          -  Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine&#xD;
             aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and&#xD;
             albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl (within 1 week prior to randomization);&#xD;
&#xD;
          -  Written informed consent for participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primarily evaluated as resectable&#xD;
&#xD;
          -  Failed to converse&#xD;
&#xD;
          -  Patients with known hypersensitivity reactions to any of the components of the study&#xD;
             treatments.&#xD;
&#xD;
          -  Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding&#xD;
&#xD;
          -  Other previous malignancy within 5 years&#xD;
&#xD;
          -  Known drug abuse/ alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu</last_name>
    <phone>+8613501984869</phone>
    <phone_ext>+8613501984869</phone_ext>
    <email>xujmin@aiiyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianmin Xu</last_name>
      <phone>18834823867</phone>
      <phone_ext>18834823867</phone_ext>
      <email>13301050195@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

